08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Mylan deal

Valeant divested generic versions of dermatology drugs BenzaClin clindamycin/benzoyl peroxide gel and Efudex fluorouracil cream to Mylan. The deal includes an ANDA for generic BenzaClin to treat acne and a license to manufacture and market...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Sanofi deal

Valeant will acquire Sanofi's Dermik dermatology unit for $425 million in cash. Dermik, which markets therapeutic and aesthetic dermatology products mainly in the U.S. and Canada, had total 2010 revenue of about $240 million. Valeant...
00:18 , Jul 12, 2011 |  BC Extra  |  Company News

Sanofi sells dermatology business to Valeant

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) acquired the Dermik dermatology unit from Sanofi (Euronext:SAN; NYSE:SNY) for $425 million in cash. Dermik, which markets therapeutic and aesthetic dermatology products mainly in the U.S. and Canada, had...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Company News

A.P. Pharma, Paul Capital Partners deal

A.P. Pharma received the final $2.5 million milestone payment from Paul Capital's Paul Royalty Fund under a 2005 deal in which Paul Capital purchased royalty rights to A.P. Pharma's acne drug Retin-A Micro and actinic...
07:00 , Sep 8, 2008 |  BioCentury  |  Regulation

Refinement wanted

Refinement wanted...
07:00 , Jun 11, 2007 |  BC Week In Review  |  Company News

A.P. Pharma, Paul Capital Partners deal

APPA received a $2.5 million milestone payment from Paul Capital's Paul Royalty Fund under a deal in which Paul Capital purchased royalty rights to acne drug Retin-A Micro and actinic keratosis drug Carac (see BioCentury,...
08:00 , Jan 23, 2006 |  BC Week In Review  |  Company News

A.P. Pharma, J&J, Paul Capital Partners sales and marketing update

A.P. Pharma Inc. (APPA), Redwood City, Calif.   Johnson & Johnson (JNJ), New Brunswick, N.J.   Paul Capital Partners , New York, N.Y.   Business: Dermatology   Paul Capital's Paul Royalty Fund purchased royalty rights...
08:00 , Feb 28, 2005 |  BC Week In Review  |  Clinical News

Carac 5-fluorouracil dermatology data

Data from a 12-month, placebo-controlled study in 142 patients showed that treatment with 0.5% Carac cream prior to cryosurgery is significantly more effective in reducing AK lesions than placebo plus cryosurgery. After 4 weeks, mean...
07:00 , Apr 16, 2001 |  BC Week In Review  |  Company News

Advanced Polymer sales and marketing update

APOS partner Dermik Laboratories Inc., a subsidiary of Aventis S.A. (AVE, Strasbourg, France), launched APOS's Carac Microsponge formulation of 5-FU to treat actinic keratoses. APOS will receive royalties. Advanced Polymer Systems Inc. (APOS), Redwood City,...